Vimarsana
Biggest News Aggregation in the World

Page 41 - Please Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Please Contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Please Contact Today - Breaking & Trending Today

NDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTC:NDATF) provides an operational update - Vimarsana News

NDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTC:NDATF) provides an operational update

  Calgary, Alberta – TheNewswire -June 12, 2023 -nDatalyze Corp. provides an operational update. The Corporation announces that it has completed its gathering of marketing statistics... | June 12, 2023

Reyna Silver Corp.: Reyna Silver Increases Claims at Medicine Springs to 6,500 Ha - Vimarsana News

Reyna Silver Corp.: Reyna Silver Increases Claims at Medicine Springs to 6,500 Ha

VANCOUVER, BC and HONG KONG, CHINA / ACCESSWIRE / June 9, 2023 / Reyna Silver Corp. (TSXV:RSLV)(OTCQX:RSNVF)(FRA:4ZC) ("Reyna' or the "Company") is pleased to announce the filing of 210 new claims (1,730

CoinWeek Terms of Use, Disclaimers, Copyright and Privacy Policies - Vimarsana News

CoinWeek Terms of Use, Disclaimers, Copyright and Privacy Policies

CoinWeek LLC [CoinWeek] Terms of Use Policy offers its web site on an “as is” basis with specific restrictions.

White Gold Corp. Files Technical Report for its Flagship - Vimarsana News

White Gold Corp. Files Technical Report for its Flagship

TORONTO, June 08, 2023 (GLOBE NEWSWIRE) -- White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the "Company") is pleased to announce it has filed a...

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA - Vimarsana News

KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it is supporting...